Genetic Test Predicts Treatment Response to ACE Inhibitor Therapy

EGMN -- Genetic profiling can identify the roughly one-fourth of patients with stable coronary artery disease who will not obtain clinical benefit from ACE inhibitor therapy, as well as a far larger group of superresponders.